T细胞恶性肿瘤的新型靶向疗法
Novel Targeted Therapies for T-Cell Malignancies.
作者信息
Tesio Melania
机构信息
UR LIB "Lymphoma Immune Biology"-INSERM U111, Centre International de Recherche en Infectiologie (CIRI), 69007 Lyon, France.
出版信息
Cancers (Basel). 2022 Aug 16;14(16):3955. doi: 10.3390/cancers14163955.
Abstract
T-cell malignancies comprise a heterogeneous group of cancers resulting from the clonal expansion of T-cells at different developmental stages [...].
摘要
T细胞恶性肿瘤是一组异质性癌症，由不同发育阶段的T细胞克隆性扩增引起[...]。
相似文献
1
Novel Targeted Therapies for T-Cell Malignancies.T细胞恶性肿瘤的新型靶向疗法
Cancers (Basel). 2022 Aug 16;14(16):3955. doi: 10.3390/cancers14163955.
2
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.在全身循环中，CD8 T细胞的克隆性扩增先于伊匹单抗诱导的毒性反应的发生。
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11919-11924. doi: 10.1073/pnas.1611421113. Epub 2016 Oct 3.
3
The Potential Roles and Advantages of Single Cell Sequencing in the Diagnosis and Treatment of Hematological Malignancies.单细胞测序在血液系统恶性肿瘤诊断和治疗中的潜在作用和优势。
Adv Exp Med Biol. 2018;1068:119-133. doi: 10.1007/978-981-13-0502-3_10.
4
Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.嵌合抗原受体 T 细胞（CAR-T）治疗 T 细胞恶性肿瘤。
Best Pract Res Clin Haematol. 2019 Dec;32(4):101097. doi: 10.1016/j.beha.2019.101097. Epub 2019 Oct 18.
5
Detection of clonally rearranged T-cell-receptor gamma chain genes from T-cell malignancies and acute inflammatory rheumatic disease using PCR amplification, PAGE, and automated analysis.运用聚合酶链反应扩增、聚丙烯酰胺凝胶电泳及自动分析技术，检测T细胞恶性肿瘤和急性炎性风湿性疾病中克隆性重排的T细胞受体γ链基因。
Ann Hematol. 1997 Mar;74(3):123-30. doi: 10.1007/s002770050269.
6
[Leukemia stem cell and clonal evolution].[白血病干细胞与克隆进化]
Nihon Rinsho. 2014 Jun;72(6):1012-7.
7
Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer.肿瘤浸润淋巴细胞过继性细胞疗法：克隆性新抗原靶点对非小细胞肺癌下一代产品的重要性日益凸显。
Immunooncol Technol. 2019 Oct 9;3:1-7. doi: 10.1016/j.iotech.2019.09.003. eCollection 2019 Oct.
8
Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies: a single-institution study of 225 cases.成熟 T 细胞淋巴母细胞恶性肿瘤患者的临床特征和预后因素：单中心 225 例研究。
Front Med. 2015 Dec;9(4):468-77. doi: 10.1007/s11684-015-0419-6. Epub 2015 Nov 11.
9
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.分子靶向药物联合治疗在髓系和淋巴系血液系统恶性肿瘤中显示出选择性疗效。
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563. doi: 10.1073/pnas.1703094114. Epub 2017 Aug 7.
10
Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication.皮肤T细胞淋巴瘤来源的克隆性辅助性T细胞2细胞的干扰素抗性允许选择性病毒复制。
Blood. 2001 Jan 15;97(2):523-7. doi: 10.1182/blood.v97.2.523.
本文引用的文献
1
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.随机 3 期 ALCANZA 研究比较 brentuximab vedotin 与皮肤科医生选择治疗皮肤 T 细胞淋巴瘤：最终数据。
Blood Adv. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710.
2
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.供体来源的 CD7 嵌合抗原受体 T 细胞治疗 T 细胞急性淋巴细胞白血病：首次人体、I 期临床试验。
J Clin Oncol. 2021 Oct 20;39(30):3340-3351. doi: 10.1200/JCO.21.00389. Epub 2021 Jul 29.
3
Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.本妥昔单抗维迪昔与化疗联合治疗 ALK+ ALCL 儿科患者：COG 试验 ANHL12P1 的结果。
Blood. 2021 Jul 1;137(26):3595-3603. doi: 10.1182/blood.2020009806.
4
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.BH3分析确定鲁索替尼是维奈托克治疗T细胞幼淋巴细胞白血病的有前景的联合用药。
Blood. 2021 Jun 24;137(25):3495-3506. doi: 10.1182/blood.2020007303.
5
Novel targeted therapies of T cell lymphomas.T 细胞淋巴瘤的新型靶向治疗。
J Hematol Oncol. 2020 Dec 31;13(1):176. doi: 10.1186/s13045-020-01006-w.
6
Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome.蕈样肉芽肿和/或塞扎里综合征患者的新治疗靶点：表型标志物、分子突变和免疫微环境。
J Invest Dermatol. 2021 Mar;141(3):484-495. doi: 10.1016/j.jid.2020.07.026. Epub 2020 Nov 5.
7
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.T滤泡辅助细胞表型可预测复发/难治性外周T细胞淋巴瘤对组蛋白去乙酰化酶抑制剂的反应。
Blood Adv. 2020 Oct 13;4(19):4640-4647. doi: 10.1182/bloodadvances.2020002396.
8
FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients.FDA 批准摘要：达肝素钠用于治疗儿科有症状的静脉血栓栓塞症。
Pediatr Blood Cancer. 2020 Dec;67(12):e28688. doi: 10.1002/pbc.28688. Epub 2020 Sep 8.
9
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.一项关于Tenalisib（RP6530）的I/Ib期研究，Tenalisib是一种双重PI3Kδ/γ抑制剂，用于复发/难治性T细胞淋巴瘤患者。
Cancers (Basel). 2020 Aug 15;12(8):2293. doi: 10.3390/cancers12082293.
10
Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults.T 细胞急性淋巴细胞白血病中青少年和成年人的生物学和治疗范例。
Curr Treat Options Oncol. 2020 May 28;21(7):57. doi: 10.1007/s11864-020-00757-5.
Zotero 插件